Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Ofatumumab works for elderly CLL patients with poor performance status, comorbidities

13 Jan 2020

Ofatumumab alone is safe and effective for treatment-naïve elderly adults with chronic lymphocytic leukaemia (CLL), regardless of comorbidities, a recent study has shown.

The phase II investigation included 34 elderly CLL patients (median age, 73 years; 20 females) who had poor performance status, as determined by the Eastern Cooperative Oncology Group (ECOG) criteria, and comorbidities. Intravenous ofatumumab was given weekly for the first month and then monthly for the following 11 months.

Two patients discontinued within the first month and were excluded from subsequent analyses. Of the remaining 32 participants, 23 had documented treatment response, resulting in an overall response rate (ORR) of 72 percent. Six (19 percent) had complete response, and 17 (53 percent) showed partial response.

Higher ofatumumab doses appeared to be more effective. Nineteen of 24 patients who received the 2,000-mg dose were documented to have responded to the drug, yielding a response rate of 79 percent. In comparison, only four of eight patients who were given the 1,000-mg dose responded, with a corresponding rate of 50 percent.

After a median follow-up of 48 months, disease progression was reported in 65 percent of the sample. The resulting median progression-free survival (PFS) time was 21 months. This varied according to treatment response. PFS was better in those who achieved complete than partial or less response (26 vs 16 months; p=0.009).

In terms of safety, grade 1 and 2 infusion-related adverse events occurred in 56 percent of the participants, and one had a grade 3 reaction. Similarly, grade 1 and 2 infectious side effects were reported, though only one reached grade 3 severity. No grade 4 adverse events were reported.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.